Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Systemic Vasculitis Clear all
Active, not recruiting Phase 3 Interventional

The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach

NCT01933724
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Wegener Granulomatosis, Vasculitis
Interventions
5 mg prednisone, 0 mg prednisone
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 1Phase 2 Interventional

Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome

NCT00266565
View directory record Official record
Conditions
Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis, Churg-Strauss Syndrome, Eosinophilic Esophagitis
Interventions
Mepolizumab
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Jul 22, 2026, 11:58 AM EDT
Completed No phase listed Observational

The ANCA Vasculitis Questionnaire (AAV-PRO©)

NCT02507024
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (Wegener's) (GPA), Wegener Granulomatosis (WG), Microscopic Polyangiitis (MPA), ANCA-Associated Vasculitis (AAV), Vasculitis
Interventions
Online questionnaire
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 1 Interventional

Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis

NCT00001761
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis
Interventions
Interleukin-10
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 11:58 AM EDT
Terminated Phase 4 Interventional Results available

Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")

NCT00747461
View directory record Official record
Conditions
Lung Diseases, Obstructive, Sarcoidosis, Wegener's Granulomatosis, Rhinoscleroma, Recurrent Respiratory Papillomatosis
Interventions
CryoSpray Ablation
Device
Lead sponsor
CSA Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Jul 22, 2026, 11:58 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

NCT04157348
View directory record Official record
Conditions
Eosinophilic Granulomatous Vasculitis
Interventions
Benralizumab, Mepolizumab, Placebo to Mepolizumab, Placebo to Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Denver, Colorado • Ann Arbor, Michigan • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 22, 2026, 11:58 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

NCT06733935
View directory record Official record
Conditions
Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis
Interventions
NKX019, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Nkarta, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
15
States / cities
Orange, California • Gainesville, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 11:58 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis

NCT02257866
View directory record Official record
Conditions
Takayasu's Arteritis, Giant Cell Arteritis, Polyarteritis Nodosa, Relapsing Polychondritis, ANCA-Associated Vasculitis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
3 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2050
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 11:58 AM EDT
Completed No phase listed Observational

Determining Disease Activity Biomarkers in Individuals With Polyarteritis Nodosa

NCT00315406
View directory record Official record
Conditions
Polyarteritis Nodosa
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
7
States / cities
Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Jul 22, 2026, 11:58 AM EDT
Recruiting No phase listed Observational

Lupus Landmark Study: A Prospective Registry and Biorepository

NCT05934149
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Lupus Research Alliance
Other
Eligibility
18 Years to 110 Years
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 11:58 AM EDT
Terminated Phase 4 Interventional Results available

Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing

NCT02749292
View directory record Official record
Conditions
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions
Rituximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 82 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jul 22, 2026, 11:58 AM EDT
Withdrawn No phase listed Observational

Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study

NCT03182049
View directory record Official record
Conditions
Granulomatosis With Polyangiitis
Interventions
Airway assessment, Rheumatology assessment
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis

NCT00104299
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
Interventions
Rituximab plus cyclophosphamide placebo (rituximab group), Cyclophosphamide plus rituximab placebo (control group), Azathioprine, Methylprednisolone (or other glucocorticoid), Prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Jul 22, 2026, 11:58 AM EDT
Recruiting Phase 2 Interventional

Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

NCT02947945
View directory record Official record
Conditions
Asthma
Interventions
Reslizumab
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 2 Interventional

Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes

NCT00004567
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 2Phase 3 Interventional

Etanercept for Wegener's Granulomatosis

NCT00005007
View directory record Official record
Conditions
Wegener's Granulomatosis
Interventions
Etanercept
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
11 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
8
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Jul 22, 2026, 11:58 AM EDT
Active, not recruiting Phase 1 Interventional

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

NCT06294236
View directory record Official record
Conditions
Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
Interventions
SC291
Biological
Lead sponsor
Sana Biotechnology
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 22, 2026, 11:58 AM EDT
Terminated Not applicable Interventional

Resistance Exercise in Rheumatic Disease

NCT01599260
View directory record Official record
Conditions
Rheumatoid Arthritis, Systemic Vasculitis
Interventions
Resistance Exercise
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Jul 22, 2026, 11:58 AM EDT
Completed No phase listed Observational

Educational Needs of Patients With Systemic Vasculitis

NCT02190929
View directory record Official record
Conditions
Behcet's Disease, Churg-Strauss Syndrome, Vasculitis, Central Nervous System, Giant Cell Arteritis, Wegener Granulomatosis, Henoch-Schoenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Jul 22, 2026, 11:58 AM EDT
Not listed No phase listed Observational

Feasibility of an Immersive Virtual Reality Based Biofeedback Intervention for Outpatients in Rheumatology

NCT03459274
View directory record Official record
Conditions
Rheumatoid Arthritis, Systemic Lupus Erythematosus, Spondyloarthropathy, Vasculitis
Interventions
VR-Biofeedback
Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Jul 22, 2026, 11:58 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Libman-Sacks Endocarditis as a Cause of Neuropsychiatric Systemic Lupus Erythematosus

NCT00858884
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Jul 22, 2026, 11:58 AM EDT
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants

NCT05988034
View directory record Official record
Conditions
Electrocardiography
Interventions
Avacopan, Moxifloxacin, Placebo for avacopan, Placebo for moxifloxacin
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment

NCT06004934
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Avacopan
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Jul 22, 2026, 11:58 AM EDT